Edgewise Therapeutics Exits Muscular Dystrophy Business for Up to $2.65 Billion
Event summary
- Edgewise Therapeutics sold its muscular dystrophy business, including sevasemten, to Servier for $1.55 billion upfront and up to $1.1 billion in milestones.
- The deal strengthens Edgewise's balance sheet and refocuses the company on cardiovascular therapies.
- Edgewise received $1.55 billion in cash upfront and is eligible for an additional $1.1 billion in milestone payments.
- Edgewise plans to use proceeds to fund development of EDG-7500 through potential approval and advance its cardiovascular pipeline.
The big picture
Edgewise Therapeutics' exit from the muscular dystrophy space marks a strategic pivot toward cardiovascular diseases, aligning with industry trends favoring focused therapeutic portfolios. The $1.55 billion upfront payment significantly bolsters Edgewise's financial position, enabling it to pursue high-value cardiovascular indications. Servier's acquisition reflects its ambition to become a key player in rare neurology, particularly in muscular dystrophy treatments.
What we're watching
- Pipeline Execution
- Whether Edgewise can successfully initiate and complete Phase 3 trials for EDG-7500 in hypertrophic cardiomyopathy by Q4 2026.
- Financial Flexibility
- How the upfront proceeds will be allocated to advance EDG-7500 and EDG-15400 through key value-inflection points.
- Regulatory Milestones
- The pace at which Servier can achieve regulatory approvals for sevasemten in Becker and Duchenne muscular dystrophy.
Related topics